VANCOUVER, British Columbia, March 14, 2019 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that early testing with its breath collection unit (“BCU”) has thus far provided stable and consistent results. In late January, the Company received an initial version of its portable handheld device for the collection of breath samples at the point of care. Testing with human subjects using the BCU, has improved consistency of breath sample collection, and has provided important real-time data parameters on breath flow rate, volume, relative humidity, carbon dioxide levels, and temperature. Engineers may make additional adjustments to the BCU based on this early testing of the unit and additional units are planned to be built for field testing purposes.



The Company also reports recent characterization work with the Cannabix’s FAIMS (field asymmetric waveform ion mobility spectrometry) THC detection device has shown the ability to supress a range of ions (both low mass and high mass) from the spectrum allowing for THC (∆9-tetrahydrocannabinol) detection from both human breath and standards. In particular, scientists are working quickly to finalize specific FAIMS geometries that will allow for optimal ion filtering capability. FAIMS works as an “ion blocking” technology, essentially blocking unwanted ions/analytes and allowing specified ions (like THC) to pass through for detection.

In addition to THC, Cannabix scientists are using FAIMS to detect two key metabolites of THC, being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards and in breath.



Marijuana contains several cannabinoids in addition to THC, several of which are metabolized in the body relatively quickly and have shorter half-lives. THC can be detectable in blood for weeks; whereas, metabolites such as 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol are only detectable for a few hours after consumption of cannabis. The detection of THC and its metabolites in human breath provides for real-time pharmacokinetic analysis. Such analysis provides a method for the identification of “recency of use” that will be important for determining impairment at the roadside. Detection capability of the metabolites provides analysis of frequent users of marijuana who tend to retain THC in their body for longer periods of time, relative to infrequent marijuana users who tend to clear THC from their body more quickly. This data and analysis will be important for an eventual court approved device. Furthermore, 11-nor-9- carboxy-tetrahydrocannabinol is the primary metabolite from the liver, which is prevalent from the consumption of edibles.



Additional improvements and IP

Engineers have improved on the design of the ionization source for the instrument which now allows for greater voltage control and precision, leading to greater signal and sensitivity. Furthermore, improvements have been made to the instrument’s heat control module. The Company’s patent portfolio includes an exclusive worldwide license of University of Florida (“UF”) US Patent 8,237,118 in the area of breath analysis of controlled substances. Additionally, the Company has licensed patent pending technology from UF (PCT/CA2017/000042), and has made its own patent applications since 2015. The Company’s technology has significantly progressed since its original filings and new intellectual property and trade secrets have been developed that will ultimately supersede earlier broad patent applications. Additional patent applications will be filed in due course.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects previous usage from days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO

Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements



This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.